206 related articles for article (PubMed ID: 22408058)
1. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Pressey JG; Haas MC; Pressey CS; Kelly VM; Parker JN; Gillespie GY; Friedman GK
Pediatr Blood Cancer; 2013 Jan; 60(1):45-52. PubMed ID: 22408058
[TBL] [Abstract][Full Text] [Related]
2. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres.
Walter D; Satheesha S; Albrecht P; Bornhauser BC; D'Alessandro V; Oesch SM; Rehrauer H; Leuschner I; Koscielniak E; Gengler C; Moch H; Bernasconi M; Niggli FK; Schäfer BW;
PLoS One; 2011; 6(5):e19506. PubMed ID: 21602936
[TBL] [Abstract][Full Text] [Related]
3. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
[TBL] [Abstract][Full Text] [Related]
4. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.
Yoon JW; Lamm M; Chandler C; Iannaccone P; Walterhouse D
BMC Cancer; 2020 Jun; 20(1):511. PubMed ID: 32493277
[TBL] [Abstract][Full Text] [Related]
6. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
[TBL] [Abstract][Full Text] [Related]
7. CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma.
Kimura T; Wang L; Tabu K; Nishihara H; Mashita Y; Kikuchi N; Tanino M; Hiraga H; Tanaka S
Cancer Invest; 2012 Jun; 30(5):390-7. PubMed ID: 22571340
[TBL] [Abstract][Full Text] [Related]
8. CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation.
Fukamachi H; Shimada S; Ito K; Ito Y; Yuasa Y
Cancer Sci; 2011 Jul; 102(7):1313-21. PubMed ID: 21457403
[TBL] [Abstract][Full Text] [Related]
9. Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines.
Nunukova A; Neradil J; Skoda J; Jaros J; Hampl A; Sterba J; Veselska R
Int J Mol Med; 2015 Jul; 36(1):65-72. PubMed ID: 25977066
[TBL] [Abstract][Full Text] [Related]
10. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin.
Friedman S; Lu M; Schultz A; Thomas D; Lin RY
PLoS One; 2009; 4(4):e5395. PubMed ID: 19404394
[TBL] [Abstract][Full Text] [Related]
11. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.
Wolf SJ; Huynh T; Bryce NS; Hambley TW; Wakelin LP; Stewart BW; Catchpoole DR
BMC Cell Biol; 2011 Aug; 12():36. PubMed ID: 21861933
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
13. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.
Suetsugu A; Nagaki M; Aoki H; Motohashi T; Kunisada T; Moriwaki H
Biochem Biophys Res Commun; 2006 Dec; 351(4):820-4. PubMed ID: 17097610
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
Dobson CC; Naing T; Beug ST; Faye MD; Chabot J; St-Jean M; Walker DE; LaCasse EC; Stojdl DF; Korneluk RG; Holcik M
Oncotarget; 2017 Jan; 8(2):3495-3508. PubMed ID: 27966453
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.
Dallas NA; Xia L; Fan F; Gray MJ; Gaur P; van Buren G; Samuel S; Kim MP; Lim SJ; Ellis LM
Cancer Res; 2009 Mar; 69(5):1951-7. PubMed ID: 19244128
[TBL] [Abstract][Full Text] [Related]
19. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines.
Sana J; Zambo I; Skoda J; Neradil J; Chlapek P; Hermanova M; Mudry P; Vasikova A; Zitterbart K; Hampl A; Sterba J; Veselska R
Anal Cell Pathol (Amst); 2011; 34(6):303-18. PubMed ID: 22156015
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
